Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.0955 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Sari L Reisner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor. Hauptthemen laut MEDLINE: Transgender Persons, Depression, Gender-Affirming Procedures. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Depression
Abstract (Originalsprache)
Importance In the US, transgender, nonbinary, and gender diverse (TGD) adults have high rates of depression. Gender-affirming hormone therapy (GAHT) is associated with improved mental health outcomes, yet existing US studies have short follow ups and lack sample diversity.
Objective
To evaluate the use of GAHT delivered in primary care as an intervention for moderate-to-severe depressive symptoms in diverse TGD adult patients. Design, Setting, and Participants LEGACY was an observational cohort study conducted in federally qualified community health centers in Boston and New York that followed up TGD patients (N = 3592) from calendar years 2016 to 2019 (48 months). Participants included individuals aged 18 years or older, gender identity different from sex at birth, a past 12-month medical visit, and signed patient consent form in the electronic health record (EHR). Exposures Prescriptions for GAHT obtained from EHR data, using the date of the first and last GAHT prescription in each calendar year of observation (GAHT within the year vs no GAHT during the year). Main Outcomes and Measures A binary outcome of patient-reported moderate-to-severe depressive symptoms was obtained using the validated Patient-Health Questionnaire (PHQ), scoring 10 or greater on the PHQ-9 or scoring 3 or greater on the PHQ-2. Following multiple imputation, generalized estimating equations (GEE) longitudinally modeled GAHT and moderate-to-severe depressive symptoms (n = 20 320 observations) and adjusted for age, gender identity, race and ethnicity, health insurance, federal poverty level, HIV serostatus, number of cohort years, and clinical site.
Results
The median age of the 3592 patients was 28 (IQR, 24-36) years. Race and ethnicity was diverse (1.3% Asian/Pacific Islander, 11.7% Black, 16.1% Hispanic/Latinx, 63.1% White, 6.8% multiracial, and 1.4% other). In addition, 18.9% were nonbinary, 52.1% lived below the federal poverty level, 34.2% were publicly insured, 4.1% were uninsured, and 5.1% were living with HIV. At baseline, 84.5% of the individuals were prescribed GAHT and 15.3% reported moderate-to-severe depressive symptoms. Patients prescribed GAHT had a statistically significantly lower risk of moderate-to-severe depressive symptoms over follow-up compared with those not prescribed GAHT (adjusted risk ratio, 0.85; 95% CI, 0.75-0.98). Conclusions and Relevance In this longitudinal observational cohort study, GAHT was associated with lower rates of moderate-to-severe depressive symptoms, highlighting the importance of gender-affirming primary care models for TGD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.
- Center for Social Epidemiology and Population Health, University of Michigan, Ann Arbor.
- Eisenberg Family Depression Center, University of Michigan, Ann Arbor.
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
- The Fenway Institute, Fenway Health, Boston, Massachusetts.
- Department of Psychiatry, Massachusetts General Hospital, Boston/Harvard Medical School, Boston.
Zitieren
APA
Reisner, S. L., Pletta, D. R., Keuroghlian, A. S., Mayer, K. H., Deutsch, M. B., Potter, J., Hughto, J. M. W., Harris, A., & Radix, A. E. (2025). Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.0955
Vancouver
Reisner SL, Pletta DR, Keuroghlian AS, Mayer KH, Deutsch MB, Potter J, et al. Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.0955
BibTeX
@article{Reisner2025,
author = {Reisner, Sari L and Pletta, David R and Keuroghlian, Alex S and Mayer, Kenneth H and Deutsch, Madeline B and Potter, Jennifer and Hughto, Jaclyn M W and Harris, Alexander and Radix, Asa E},
title = {Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.0955}
}
EUVIMED